My watch list  


Systematic (IUPAC) name
CAS number 121032-29-9
ATC code L01BB07
PubChem 3011155
Chemical data
Formula C11H15N5O5 
Mol. mass 297.268 g/mol
Pharmacokinetic data
Bioavailability n/a
Protein binding <25%
Metabolism By adenosine deaminase, to 9-β-D-arabinofuranosylguanine
Half life 30 minutes (nelarabine)
3 hours (ara-G)
Excretion Renal
Therapeutic considerations
Pregnancy cat.


Legal status


Routes Intravenous

Nelarabine is a chemotherapy drug used in T-cell acute lymphoblastic leukemia. It was previously known as 506U78.

Nelarabine is a purine nucleoside analog converted to its corresponding arabinosylguanine nucleotide triphosphate (araGTP), resulting in inhibition of DNA synthesis and cytotoxicity. Pre-clinical studies suggest that T-cells are particularly sensitive to nelarabine. In October 2005, it was approved by the FDA for T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma that has not responded to or has relapsed following treatment with at least two chemotherapy regimens. Complete responses have been achieved with this medication.

It is marketed as Arranon by GlaxoSmithKline.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Nelarabine". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE